The End of the Regulatory Vacuum in Europe and a New Era for International Arbitration In Ireland? Developments in Third-Party Funding Regulation
Alert
CFIUS Issues New Enforcement and Penalty Guidelines
Alert
EU designates Iranian persons over domestic human rights situation and supplies of drones to Russia
Alert
DOJ Announces Seven Director Resignations from Five US Public Company Boards in the Most Recent Wave of Reinvigorated Clayton Act Section 8 Enforcement
Article
ICLG: Sanctions 2023 (Fourth Edition)
Article
Website terms of service – enforceable or preempted?
Alert
Biden Executive Order Seeks to Solidify European Union-U.S. Data Privacy Framework
Alert
Summary of FERC Meeting Agenda for October 2022
Article
You’ve been Airdropped: English Courts Approve Service of Lawsuit via NFT
Alert
US Trade Representative Seeks Public Comments in Four-Year Review of Section 301 Tariffs on Products of China
Article
United States: Pharmaceutical Antitrust 2023
Alert
Upcoming California Privacy Rights Act: Key Compliance Tasks for California Employers
Alert
The Framework for Cooperation between the European Public Prosecutor's Office and Non-EU Third Countries
Treatment of Employee Equity Awards in Corporate Mergers and Acquisitions
Alert
Negotiations on Carbon Credits Expected to Continue at COP27
Alert
Summary of FERC Meeting Agenda for September 2022
Alert
Biden Issues First-Ever Presidential Directive Defining National Security Factors for CFIUS to Consider in Evaluating Transactions
Alert
IPEF Ministers Outline Negotiating Objectives, Setting Stage for Formal Negotiations
Article
GIR's Americas Investigations Review 2023
Alert
2022 Drug Pricing Update: States Continue Legislative Push Even As Congress Passes Long Sought Changes
Alert
Mexico Nationalizes Lithium; Sets Up State-Owned Company
Alert
SEC Adopts Pay Versus Performance Disclosure Rules
Alert
Aviation Arbitration Center with Global Reach Launches In The Hague
Insight
US utilities M&A remains resilient in H1
M&A Explorer | Positive tailwinds such as the global shift to clean energy sources and the need to replenish infrastructure are driving dealmaking in the sector
Alert
California Attorney General Bark Turns to Bite as First CCPA Settlement Includes Monetary Penalty
Alert
PCAOB and Chinese Authorities Sign Agreement, Taking First Step Toward Complete Access for PCAOB to Inspect and Investigate Auditors in China and Hong Kong
Alert
Reminder: Voluntary ISS Annual Benchmark Policy Survey Due by August 31st
Alert
Immigration Reform: The Federal Reserve should adopt the 2019 Volcker Rule revisions as the standard for how foreign banks can engage in nonbanking activities within the United States
Insight
M&A Explorer
Insights from our M&A team, based on M&A activity charts from the White & Case M&A Explorer.
Insight
Reality check: US M&A H1 2022
US deal activity saw an annual decrease in H1 of this year, but remains buoyant compared to pre-pandemic standards
Insight
What’s next for US M&A?
Five factors that will shape dealmaking over the coming 12 months
Insight
Notable decisions from Delaware courts
In the first half of 2022, Delaware courts issued several important decisions affecting M&A dealmaking
Insight
Walking the tightrope of Russia sanctions
Buying an asset with operations in Russia remains permissible under sanctions laws, but any such process must be carefully considered
Insight
SEC: The watchdog bares its teeth
The SEC has followed through on promises to increase enforcement
Insight
Antitrust enforcement set to ramp up in H2
New appointments in both the FTC and DOJ signal greater enforcement action on the horizon—with buyout firms a particular target
Insight
Real estate M&A defies downturn expectations in H1
Red-hot demand for warehouse space drove dealmaking in the sector in H1
Insight
Retail M&A is out of favor for now, but quality consumer brands stand strong
Deal activity in consumer and retail decline as inflation worries hit confidence
Insight
Big pharma firms return to the deal table in H1
Cash-rich pharma firms look set for a buying spree, as favorable biotech valuations and patent expirations incentivize dealmaking
